Revita Life Sciences



It is because of mismatch between bone production and osteolysis with the latter occurring at a relatively faster rate. This  leads to the death of the bony trabeculae supporting the articular cartilage.

Reduction of mesenchymal stem cells (MSCs) in the bone marrow while enhanced  number of adipose cells and apoptotic cells is seen in AVN heads.

Core decompression (CD) is  devised to release the intraosseous pressure and increase the blood flow to the femoral head, so as to prevent progression or reverse the pathology of AVN.

It has had promising results in very early stages of AVN, wherein cores of subchondral deadbone are removed by drilling, facilitating blood vessel in growth and restoration of vascularity.

CD alone in FICAT Stage 1 has shown promising results with reversal rates of up to 97% .

The success of the same procedure in  FICAT Stage 2  goes down to 77%.Therefore, lies the need of adding biological to increase its efficacy.


Heads not progressed to head distortion and collapseonly up to crescent sign and <50% involvement.


Core decompression plus  biological preferably bone marrow.30  of MNC concentrate prepared from mean volume of 180 ml aspirate

Trocar is placed under C-Arm control into the lesion

Stem cells are injected with a catheter

Hole sealed with bone plug

Results: At 2 yr

Mean volume of necrotic lesion reduced  by 30 percent  at 24 months

90% patients – significant improvement in Harris Hip scores (HHS>80,).

90% patients  — improvement of   60% or more  in their pain intensities.

The lesions shrank significantly in 60% of ARCO I and II cases

Progression of disease to Stage III in 25 % as compared to CD only (60-70%)

10 % needed THR.